Inhalation of Low Molecular Weight Heparins as a prophylaxis to prevent SARS-CoV-2 infection
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:7 publications
Grant number: 114025008
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$634,490.21Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
PendingResearch Location
NetherlandsLead Research Institution
Amsterdam UMC (location AMC)Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Project description Existing drug prevents SARS-CoV-2 infection There is a very urgent need for SARS-CoV-2 preventive drugs to stop the COVID-19 pandemic. We have found that infection of cells with SARS-CoV-2 is blocked by the anti-clotting drug low molecular weight heparin. This drug blocks the binding of the virus to the cells, which greatly reduces or even prevents infection.In this project we will investigate whether inhalation of low molecular weight heparin can be used as a preventive drug against SARS-CoV-2. To this end, we have developed animal-free innovations to determine the effectiveness of the intervention and to unravel the mechanism of action of this drug.
Publicationslinked via Europe PMC
Last Updated:16 hours ago
View all publications at Europe PMC